Lifecore Biomedical Inc reports results for the quarter ended November 30 - Earnings Summary

Lifecore Biomedical

02/01/2025 22:02

* Lifecore Biomedical Inc  LFCR.OQ  reported a quarterly
adjusted
loss of 25 cents​​ per share for the quarter ended November 30. 
The mean expectation of three analysts for the quarter was for a
loss of 30 cents per share. Wall Street expected results to
range from -34 cents to -27 cents per share.
    * Revenue was $32.56 million​; analysts expected $29.75
million. 
    * Lifecore Biomedical Inc's reported EPS for the quarter was
a
loss of 25 cents​.
    * The company reported a quarterly loss of $8.7 million.
    * Lifecore Biomedical Inc shares had held steady so far this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 22%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "hold"

Wall Street's median 12-month price target for Lifecore
Biomedical Inc is $8.00 
This summary was machine generated from LSEG data January 2 at
10:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Nov. 30 2024      -0.30          -0.25          Beat
 Aug. 31 2024      -0.46          -0.49          Missed
 May. 31 2024      -0.12          -0.17          Missed
 Feb. 29 2024      -0.06